

BRUINVELS
U.S. National Phase of PCT/GB2004/001225

AMENDMENTS TO THE ABSTRACT

Please insert the Abstract of the Disclosure which is on the attached sheet.

ABSTRACT OF THE DISCLOSURE

The present invention relates to the use of certain 5-HT_{2C} receptor antagonists in the manufacture of medicaments for the treatment of mental disorders, in particular aspects of schizophrenia, cognitive impairment and suicidality, as well as to methods for determining the suitability of compounds for such a use.